Late-stage opp Leverage Privosegtor in optic neuropathies and neuro-ophthalmology with potential expansion to other neuro-ophthalmic and neurological indications; target ophthalmology and neurology payers and patient access teams for registrational trajectories.

Topical anti-TNF Licaminlimab offers a topical, genotype-based approach for dry eye disease, presenting a direct sell-in to ophthalmology practices and payer programs focused on personalized medicine and targeted therapies.

Strategic asset Recent asset purchase aligns Oculis to fully own Privosegtor development, enabling stronger negotiation leverage with partners, CROs, and potential co-commercialization deals to accelerate market entry.

Global footprint Operations across Switzerland, the U.S., and Iceland facilitate multi-regional discussions with regional KOLs, payers, and regulators to tailor clinical strategies and market access plans.

Financial posture Recent Q2 results show ongoing investment in late-stage trials with a focus on near-term value creation; approach can attract strategic investors or licensing partners seeking near-term visibility into regulatory milestones.